Non-Purulent
e.g. cellulitis, erysipelas, necrotizing infection

Usually *Streptococcus* species

Blood cultures usually not required unless immunocompromised*, immersion injury, or associated with animal bite

Mild Infection
Typical cellulitis/erysipelas without focus of purulence

- Penicillin VK
  - 500 mg PO QID
- Dicloxacillin
  - 500 mg PO QID
- Cephalexin
  - 500 mg PO QID
- Clindamycin
  - 300 mg PO QID

Moderate Infection
Typical cellulitis/erysipelas with systemic signs of infection

- Oxacillin
  - 1-2 g IV Q4H
- Cefazolin
  - 2 g IV Q8H
- Ceftriaxone
  - 2 g IV Q24H
- Clindamycin
  - 600-900 mg IV Q8H

Severe Infection
- Patients who have failed oral antibiotics
- Immunocompromised patients
- Patients with bullae, skin sloughing, hypotension, or evidence of organ dysfunction
- Tmax > 38°C, HR > 90, RR > 24, WBC > 12,000

Emergent surgical evaluation/debridement to r/o necrotizing process

Consider ID consult

Obtain blood cultures and wound swab

- Vancomycin per Pharmacy
  - PLUS
  - Piperacillin/tazobactam
    - 4.5 g x 1 followed by 3.375 g IV Q8H extended infusion

Culture directed therapy for necrotizing infections

---

* ANC < 1000, congenital immunodeficiency, asplenia, HIV, hematologic malignancies, prednisone equivalent > 10 mg/day for 2+ weeks

* use of clindamycin and 3rd generation cephalosporins have been associated with increased risk of *Clostridium difficile* infection
Purulent
  e.g. furuncle, carbuncle, abscess

Usually Staphylococcus species

I&D with culture is primary treatment
Antibiotics only indicated for systemic illness or immunosuppression

Mild Infection
- I&D

Moderate Infection
- Purulent infection with systemic signs of infection
  - I&D
  - Empiric antibiotics
    - TMP/SMX 1 DS tablet PO BID
    - Doxycycline 100 mg PO BID
  - Culture directed therapy
    - MRSA
      - Continue previous antibiotic ordered
    - MSSA
      - Cephalexin 500 mg PO QID
    - Amoxicillin/clavulanate 875mg PO BID

Severe Infection
- Patients who have failed I&D plus oral antibiotics
- Immunocompromised patients
- Tmax > 38°, HR > 90, RR > 24, WBC > 12,000
  - I&D
  - Empiric antibiotics
    - Vancomycin Per pharmacy
    - Culture directed therapy
      - MRSA
        - Vancomycin Per pharmacy
      - MSSA
        - Oxacillin 2 g IV Q4H
        - Cefazolin 2 g IV Q8H

Antimicrobial Stewardship Committee
Approved April 2015